Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Abbvie Stemcentrx LLC

Home Clinical Trial Sponsors and OrganizationsAbbvie Stemcentrx LLC

Abbvie Stemcentrx LLC

1000 Gateway Blvd, South San Francisco, California, United States

Also known as:

Abbvie

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

5

5 active

Approvals

3

Total approvals

Agencies

2

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

5

100.0%

Trial Status Distribution

Active, not recruiting

5

100.0%

Clinical Trials

Trials sponsored by this organization (5)

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Active, not recruiting

Nov 202042 participants

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Active, not recruiting

May 201790 participants

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Active, not recruiting

May 201790 participants

An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY) - TRINITY

Active, not recruiting

Jul 2016342 participants

A Clinical Trial to observe the effects of the test drug Rovalpituzumab Tesirine in patients with a particular form of Lung Cancer where no lasting efficacy has been achieved on at least two previous therapies.

Active, not recruiting

Jan 2016230 participants

Approvals

Approvals by Agency

FDA

Food and Drug Administration

1

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

2

Approvals

Recent Approvals

VISCOFRESH 10 mg/ml COLIRIO EN SOLUCION EN ENVASE UNIDOSIS

COMBIGAN 2 MG/ML + 5 MG/ML COLIRIO EN SOLUCION

News

No news articles found

On this page

Overview
Clinical Trials5
Approvals3
News

Back to Organizations